Authored by

Ben Kaspar
Vice President, Regulatory Strategy

Artificial Intelligence (AI) is reshaping submission readiness, but the key question for sponsors is not whether to use it, but how to apply it responsibly and effectively. 

As adoption matures, a more practical understanding of AI is also emerging. Rather than treating it as a single solution, sponsors are distinguishing between tools such as machine learning for structured, data-driven tasks and large language models for interpreting and generating regulatory content. Choosing the right tool for the right task is essential to reducing risk and delivering value, which is driving a shift toward targeted, workflow-specific applications. 

Balancing Speed with Validation 

A recurring question is how to balance the pressure to adopt AI quickly with the need for appropriate validation. In practice, the most effective approach is to start with low-risk, high-impact use cases such as document review, gap analysis, or regulatory intelligence, while applying validation frameworks that reflect each tool’s intended use. 

Maintaining human oversight remains essential, particularly for decisions that affect regulatory positioning. This allows teams to move quickly where appropriate without compromising submission quality or defensibility, positioning AI as an augmented layer within existing processes rather than a replacement for expert review. 

Where AI Is Delivering Immediate Value 

AI is already delivering practical value across several areas of submission readiness. In regulatory intelligence and interpretation, it can act as a structured second opinion, helping teams assess submissions against guidance and precedent, identify gaps or inconsistencies, and stay aligned with evolving expectations. This supports stronger decision-making while improving consistency across increasingly complex submission activities. 

The same applies to quality and consistency. AI tools can help standardize document structure and language, reduce variability between contributors, and improve alignment across modules. In complex submissions, where inconsistency can add to review burden, these improvements can make the overall package clearer, more coherent, and easier to assess. 

AI can also help accelerate submission timelines, although its impact is usually incremental rather than transformational. Organizations are seeing gains in specific tasks such as document review, drafting cycles, and content refinement, with faster iteration during development and less rework overall. These efficiencies may be modest in isolation, but across a submission workflow they can contribute to a more streamlined path to filing. 

Another important benefit is the potential to reduce reviewer burden. By supporting more structured, readable, and complete submissions, AI can improve traceability, limit avoidable follow-up questions, and make information easier for regulators to navigate. In that sense, its value is not only in helping sponsors work more efficiently, but also in strengthening the quality of the final submission in ways that support a more efficient review process. 

AI as an Extension of Regulatory Expertise 

Across all use cases, one theme remains consistent: AI is most effective when used alongside experienced regulatory professionals. It is best understood as part of the regulatory strategy toolbox, helping teams stress-test submission logic, support decision-making, and improve efficiency without compromising quality. This reflects a broader shift from automation to augmentation and raises an important related question about how regulatory frameworks are keeping pace with rapid AI innovation. 

At present, there is no single, comprehensive global framework governing AI use in regulatory submissions. However, regulators are already applying existing principles around data integrity, validation, and traceability to AI-enabled workflows, while guidance continues to evolve with greater emphasis on Good Machine Learning Practice (GMLP) and risk-based validation approaches. 

What remains consistent is the expectation that output must be reliable, explainable, and fit for purpose, regardless of how they are generated. Even as AI tools evolve, the underlying regulatory standards are unlikely to change, with continued emphasis on scientific validity, transparency, and accountability. In other words, while technology may advance quickly, the principles governing its use remain stable. 

What This Means for Sponsors 

The organizations seeing the most value from AI are not those moving fastest, but those applying it most thoughtfully. Success depends on focusing on defined, high-value use cases, scaling adoption in a controlled way, embedding AI within existing regulatory workflows, and maintaining strong oversight and validation. As AI continues to reshape submission readiness, its impact will be determined by how it is applied, not how quickly it is adopted. 

Case Study Card
Want to learn more? Watch our new webinar

How AI Is Being Applied to Accelerate Submission Readiness and Reduce Time to Filing

Explore how sponsors are moving away from broad AI adoption toward more targeted, workflow-specific use cases.

Suggested For You

perspectives

June 3rd, 2025

Choosing the Right Strategy: Parallel, Sequential, and Staggered Regulatory Submissions 

perspectives

July 22nd, 2025

Career Insights: From Military Service to Regulatory Strategy – Ritchie Patton’s Journey at MMS

regulatory intelligence

January 17th, 2025

New FDA Protocol Deviation Guidance:  Planning for the Things That Don’t Go According to Plan

news

November 8th, 2024

MMS Named a Finalist in the 2024 Fierce CRO Awards for Leadership in Regulatory Compliance

perspectives

July 16th, 2024

Key Steps to Successful CMC Authoring of IND and IMPD Submissions

perspectives

July 9th, 2024

Managing RTOR Submissions: How to Run a Successful Race from the Top Line Starting Line

perspectives

July 2nd, 2024

Part 1: RWD Noninterventional Study Design and FDA Engagement Opportunity for Early Stage Oncology

perspectives

November 2nd, 2023

Comparability Studies for Biologics: What Drug Developers Need to Succeed

perspectives

October 11th, 2023

Understanding the Revised Draft Guidance for Formal Meetings with the FDA

perspectives

August 24th, 2023

“D” is for Discipline: Everything You Need to Know About FDA's Type D Meetings

perspectives

August 2nd, 2023

Single-Arm Trials and Drug Approval in the European Union (EU)

perspectives

March 16th, 2023

New FDA Policies and Procedures for Products Submitted Under Accelerated Pathways : Understanding CDER MAPP 5015.13